Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment

Iben Daugaard, Dianna Hussmann, Louise Kristensen, Thomas Kristensen, Tina E Kjeldsen, Charlotte G Nyvold, Thomas S Larsen, Michael B Møller, Lise Lotte Hansen, Tomasz K Wojdacz

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

4 Citationer (Scopus)

Abstract

Aim: We investigated whether DNA methylation regulates expression of LPL and PI3K complex genes in chronic lymphocytic leukemia (CLL) and evaluated the prognostic significance of LPL promoter methylation in CLL patients. Patients & methods: Methylation of LPL promoter was assessed in 112 patients using methylation-sensitive high-resolution melting (MS-HRM).Results: Patients with a fully or heterogeneously methylated LPL promoter had significantly longer median time to treatment (p < 0.001) and 75% lower (hazard ratio: 0.25; 95% CI: 0.15-0.42; p < 0.001) risk of requirement for treatment as opposed to patients with nonmethylated promoter. Multivariate modeling confirmed independent prognostic value of these findings. Conclusion: Chronic lymphocytic leukemia patients with a fully or heterogeneously methylated LPL gene promoter display indolent disease course and acquisition of heterogeneous methylation of LPL promoter is insufficient to induce gene expression.

OriginalsprogEngelsk
TidsskriftEpigenomics
Vol/bind10
Nummer9
Sider (fra-til)1155-1166
Antal sider12
ISSN1750-1911
DOI
StatusUdgivet - sep. 2018

Fingeraftryk

Dyk ned i forskningsemnerne om 'Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment'. Sammen danner de et unikt fingeraftryk.

Citationsformater